Notably, the activity of EGFR-172 ADC in Raw-ISG-luc cells was >100 fold lower than its activity in THP1-ISG-luc-EGFR cells, suggesting that an ADC taken up by cells through a tumor antigen is more effective at activating the STING pathway than an ADC taken up through an Fc receptor. Here, EGFR is linked to neoplasm.